Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CorMedix Inc stock logo
CRMD
CorMedix
$13.61
+0.2%
$11.33
$3.61
$15.38
$921.06M1.621.23 million shs1.68 million shs
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
$3.99
+0.3%
$2.61
$0.72
$6.24
$257.28M2.29890,088 shs771,612 shs
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$23.88
-0.3%
$21.72
$16.16
$26.55
$971.18M0.74207,808 shs247,450 shs
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$8.67
+1.8%
$8.74
$6.50
$18.98
$901.08M0.83879,003 shs1.33 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CorMedix Inc stock logo
CRMD
CorMedix
0.00%-8.61%+5.93%+24.47%+213.63%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
0.00%0.00%+0.76%+308.58%-9.55%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
0.00%-2.24%-0.54%+9.41%+37.07%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
0.00%-8.92%-3.68%-4.59%-46.63%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CorMedix Inc stock logo
CRMD
CorMedix
1.0699 of 5 stars
2.61.00.00.02.80.00.6
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
2.6511 of 5 stars
4.23.00.00.00.62.50.0
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
3.8704 of 5 stars
0.84.02.51.12.83.32.5
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
1.6997 of 5 stars
4.50.00.00.00.51.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CorMedix Inc stock logo
CRMD
CorMedix
3.14
Buy$15.8316.34% Upside
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
2.44
Hold$11.75194.49% Upside
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1.67
Reduce$20.80-12.90% Downside
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.90
Moderate Buy$24.13178.42% Upside

Current Analyst Ratings Breakdown

Latest INZY, CRMD, PAHC, and RCUS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/20/2025
CorMedix Inc stock logo
CRMD
CorMedix
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$13.00 ➝ $17.00
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
6/16/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
BNP Paribas Exane
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Neutral$24.00
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$4.00
5/16/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$15.00 ➝ $4.00
5/14/2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
5/9/2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$24.00 ➝ $22.00
5/8/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $21.00
(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CorMedix Inc stock logo
CRMD
CorMedix
$43.47M21.23N/AN/A$1.40 per share9.72
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
N/AN/AN/AN/A$0.90 per shareN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$1.02B0.95$2.11 per share11.34$6.34 per share3.77
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$258M3.56N/AN/A$5.30 per share1.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CorMedix Inc stock logo
CRMD
CorMedix
-$17.93M$0.2261.8714.48N/A20.81%22.57%17.02%8/13/2025 (Estimated)
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$102.02M-$1.69N/AN/AN/AN/A-159.93%-82.48%8/5/2025 (Estimated)
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$2.42M$0.7830.6211.370.452.68%30.51%6.89%8/27/2025 (Estimated)
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$283M-$4.19N/AN/AN/A-258.94%-70.58%-32.97%8/4/2025 (Estimated)

Latest INZY, CRMD, PAHC, and RCUS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
-$0.43-$0.44-$0.01-$0.44N/AN/A
5/7/2025Q3 2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.52$0.63+$0.11$0.51$352.41 million$347.80 million
5/6/2025Q1 2025
CorMedix Inc stock logo
CRMD
CorMedix
$0.25$0.30+$0.05$0.30$38.90 million$39.08 million
5/6/2025Q1 2025
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$1.02-$1.14-$0.12-$1.14$38.61 million$28.00 million
3/25/2025Q4 2024
CorMedix Inc stock logo
CRMD
CorMedix
$0.17$0.22+$0.05$0.22$27.46 million$30.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CorMedix Inc stock logo
CRMD
CorMedix
N/AN/AN/AN/AN/A
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
N/AN/AN/AN/AN/A
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
$0.482.01%N/A61.54%N/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
N/AN/AN/AN/AN/A

Latest INZY, CRMD, PAHC, and RCUS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2025
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
quarterly$0.122.52%6/4/20256/4/20256/25/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CorMedix Inc stock logo
CRMD
CorMedix
N/A
4.21
3.99
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
0.65
2.19
2.19
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
2.67
2.91
1.23
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
0.09
5.37
5.37

Institutional Ownership

CompanyInstitutional Ownership
CorMedix Inc stock logo
CRMD
CorMedix
34.18%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
88.30%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
99.34%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
92.89%

Insider Ownership

CompanyInsider Ownership
CorMedix Inc stock logo
CRMD
CorMedix
5.30%
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
12.18%
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
50.07%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
9.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
CorMedix Inc stock logo
CRMD
CorMedix
3067.82 million64.23 millionOptionable
Inozyme Pharma, Inc. stock logo
INZY
Inozyme Pharma
5064.56 million56.70 millionOptionable
Phibro Animal Health Corporation stock logo
PAHC
Phibro Animal Health
1,94040.53 million20.24 millionOptionable
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
500105.89 million95.72 millionOptionable

Recent News About These Companies

Cantor Fitzgerald Comments on RCUS FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

CorMedix stock logo

CorMedix NASDAQ:CRMD

$13.61 +0.03 (+0.22%)
Closing price 04:00 PM Eastern
Extended Trading
$13.58 -0.02 (-0.18%)
As of 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Inozyme Pharma stock logo

Inozyme Pharma NASDAQ:INZY

$3.99 +0.01 (+0.25%)
Closing price 04:00 PM Eastern
Extended Trading
$3.99 0.00 (0.00%)
As of 06:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Phibro Animal Health stock logo

Phibro Animal Health NASDAQ:PAHC

$23.88 -0.08 (-0.33%)
Closing price 04:00 PM Eastern
Extended Trading
$23.89 +0.01 (+0.04%)
As of 04:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine adjuvants for animal's health and performance, food safety, and animal welfare; and engages in development, manufacturing, and marketing of microbial and bioproducts for various applications serving animal health and nutrition, environmental, industrial, and agricultural customers. In addition, the company develops, manufactures, and markets conventionally licensed and autogenous vaccine products, as well as adjuvants for animal vaccine manufacturers. Further, it provides formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds to fortify the daily feed requirements of their livestock's diets and maintain optimal balance of trace elements in animals. Additionally, the company offers specialty ingredients for personal care, industrial chemical, and chemical catalyst industries. It sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle producers, as well as through commercial animal feed manufacturers, wholesalers, and distributors. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was founded in 1946 and is headquartered in Teaneck, New Jersey.

Arcus Biosciences stock logo

Arcus Biosciences NYSE:RCUS

$8.66 +0.16 (+1.82%)
Closing price 03:59 PM Eastern
Extended Trading
$8.64 -0.03 (-0.35%)
As of 05:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.